Cyclacel Pharmaceuticals logo
Cyclacel’s Clinical Stage CDK2/9 Inhibitor Fadraciclib Targets Key Anti-Apoptotic and Oncogenic Pathways in Cancer
July 13, 2020 07:00 ET | Cyclacel
-- Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC – ...
Quanta.png
Quanta Publishes Study in PLOS ONE: Enhancement of Solute Clearance using Pulsatile Push-Pull Dialysate Flow for SC+
March 03, 2020 02:00 ET | Quanta Dialysis Technologies
Quanta Publishes Study in PLOS ONE:Enhancement of Solute Clearance using Pulsatile Push-Pull Dialysate Flow for SC+ Alcester, Warwickshire, UK, 03 March 2020: Quanta Dialysis Technologies Ltd...
Phase 2 Clinical Dat
Phase 2 Clinical Data Published Showing Summit’s Ridinilazole Preserved the Gut Microbiome of Patients with C. difficile Infection
August 02, 2018 14:00 ET | Summit Therapeutics plc
Microbiome Damage Caused by Current Treatments May Lead to Disease RecurrenceRidinilazole Reduced Recurrence Rates by 59% versus Standard of Care Vancomycin OXFORD, U.K. and CAMBRIDGE, Mass., Aug. ...
Mesoblast Cell Therapy Reduces Inflammation And Reverses Coronary Artery Dysfunction In Rheumatoid Arthritis Preclinical Study
May 12, 2015 05:08 ET | Mesoblast
NEW YORK, May 12, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB, USOTC:MBLTY) today announced publication of results in the May issue of the peer-reviewed journal PLOS One showing that its...